Dept. of Radiation Oncology (MAASTRO Lab), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands.
Dept. of Radiation Oncology (MAASTRO Lab), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands.
Radiother Oncol. 2015 Sep;116(3):352-7. doi: 10.1016/j.radonc.2015.08.022. Epub 2015 Aug 28.
Tumour hypoxia and its molecular responses have been shown to be associated with poor prognosis. Detection of hypoxia, preferably in a non-invasive manner, could therefore predict treatment outcome and serve as a tool to individualize treatment. This review gives an overview of recent literature on hypoxia imaging markers currently used in clinical trials. Furthermore, recent progress made in targeting hypoxia (hypoxia-activated prodrugs) or hypoxia response (carbonic anhydrase IX inhibitors) is summarized. Last, window-of-opportunity trials implementing non-invasive imaging are proposed as an important tool to prove anti-tumour efficacy of experimental drugs early during drug development.
肿瘤缺氧及其分子反应已被证明与预后不良有关。因此，通过非侵入性方式检测缺氧情况，可以预测治疗效果，并作为个体化治疗的工具。本文综述了目前临床试验中使用的缺氧成像标记物的最新文献，并总结了靶向缺氧（缺氧激活前药）或缺氧反应（碳酸酐酶 IX 抑制剂）的最新进展。最后，提出了机会窗试验，该试验利用非侵入性成像作为一种重要工具，在药物开发早期证明实验药物的抗肿瘤疗效。
